NASDAQ:MBX MBX Biosciences (MBX) Stock Price, News & Analysis $52.97 +2.68 (+5.33%) Closing price 04:00 PM EasternExtended Trading$52.98 +0.02 (+0.03%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About MBX Biosciences Stock (NASDAQ:MBX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MBX Biosciences alerts:Sign Up Key Stats Today's Range$50.05▼$53.6350-Day Range$48.50▼$68.6252-Week Range$16.95▼$72.64Volume492,888 shsAverage Volume647,685 shsMarket Capitalization$2.55 billionP/E RatioN/ADividend YieldN/APrice Target$87.00Consensus RatingModerate Buy Company Overview MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing peptide therapies for endocrine and metabolic disorders. The company uses its Precision Plus peptide engineering platform to design medicines intended to provide targeted biological activity, longer duration and more convenient dosing than conventional peptide treatments. MBX Biosciences’ lead program is MBX 2109, an investigational long-acting parathyroid hormone replacement therapy being developed for people with hypoparathyroidism, a disorder in which the body produces insufficient parathyroid hormone and has difficulty maintaining normal calcium levels. The company’s pipeline also includes additional preclinical and clinical-stage peptide programs addressing other endocrine diseases. Founded in 2019 and headquartered in Indianapolis, Indiana, MBX Biosciences conducts its research and clinical development activities primarily in the United States while advancing therapies intended for patients in broader international markets. Its common stock trades on the Nasdaq under the symbol MBX.AI Generated. May Contain Errors. Read More MBX Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreMBX MarketRank™: 3.344524793385 of 5 starsMBX Biosciences scored higher than 67% of companies evaluated by MarketBeat, and ranked 279th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingMBX Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on 1 strong buy rating, 10 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialMBX Biosciences has a consensus price target of $87.00, representing about 64.6% upside from its current price of $52.87.Amount of Analyst CoverageMBX Biosciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about MBX Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MBX Biosciences are expected to decrease in the coming year, from ($3.10) to ($4.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MBX Biosciences is -21.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MBX Biosciences is -21.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMBX Biosciences has a P/B Ratio of 6.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.33% of the float of MBX Biosciences has been sold short.Short Interest Ratio / Days to CoverMBX Biosciences has a short interest ratio ("days to cover") of 7.46.Change versus previous monthShort interest in MBX Biosciences has recently decreased by 0.97%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMBX Biosciences does not currently pay a dividend.Dividend GrowthMBX Biosciences does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.98 News SentimentMBX Biosciences has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for MBX Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for MBX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows3 people have added MBX Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, MBX Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $24,335.00 in company stock.Percentage Held by Insiders31.09% of the stock of MBX Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsMBX Biosciences has minimal institutional ownership at this time.Read more about MBX Biosciences' insider trading history. Receive MBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MBX Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MBX Stock News HeadlinesMbx Biosciences, Inc. Announces Appointment of Peter Radovich as Director, Effective October 20, 2026October 22, 2026 | marketscreener.comMMBX Biosciences Expands Board, Appoints New DirectorOctober 22, 2026 | tipranks.comLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for 29.97, but it's available as a free download for a limited time.October 27 at 1:00 AM | Profits Run (Ad)MBX Biosciences to Participate in Upcoming November Investor ConferencesOctober 13, 2026 | globenewswire.comIs MBX Biosciences (MBX) Still Undervalued After Its Pullback From A Strong 1 Year Run?October 10, 2026 | finance.yahoo.comMBX Biosciences (MBX) Stock Could Be Above Fair Value As Shares Jumped 257%October 9, 2026 | finance.yahoo.comMBX Biosciences出席Stifel心臟代謝論壇：管線佈局押注給藥優勢September 30, 2026 | hk.investing.comMBX Biosciences aposta em dosagem diferenciada no pipeline de obesidade e doenças rarasSeptember 30, 2026 | br.investing.comSee More Headlines MBX Stock Analysis - Frequently Asked Questions How have MBX shares performed this year? MBX Biosciences' stock was trading at $31.54 at the beginning of 2026. Since then, MBX shares have increased by 67.6% and is now trading at $52.8660. How were MBX Biosciences' earnings last quarter? MBX Biosciences, Inc. (NASDAQ:MBX) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.68) by $0.10. When did MBX Biosciences IPO? MBX Biosciences (MBX) raised $153 million in an IPO on Thursday, September 12th 2024. The company issued 10,200,000 shares at a price of $14.00-$16.00 per share. Who are MBX Biosciences' major shareholders? MBX Biosciences' top institutional investors include Sowell Financial Services LLC (0.11%), Sowell Financial Services LLC (0.11%), Koa Wealth Management LLC (0.03%) and Sterling Capital Management LLC. Insiders that own company stock include Patrick J Heron, Life Sciences X LP Frazier, Edward T Mathers, Carl L Gordon, P Kent Hawryluk, Ora H Pescovitz, Steven L Hoerter and Salomon Azoulay. View institutional ownership trends. How do I buy shares of MBX Biosciences? Shares of MBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MBX Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that MBX Biosciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Strive (ASST), AST SpaceMobile (ASTS), Celldex Therapeutics (CLDX), Definium Therapeutics (DFTX) and Bloom Energy (BE). Company Calendar Last Earnings8/06/2026Today10/27/2026Jefferies Global Healthcare Conference11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 MBX's financial health is in the Green zone, according to TradeSmith. MBX has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MBX Previous SymbolNASDAQ:MBX CIK1776111 Webmbxbio.com Phone(317) 989-3100FaxN/AEmployees63Year Founded2018Price Target and Rating Average Price Target for MBX Biosciences$87.00 High Price Target$150.00 Low Price Target$18.00 Potential Upside/Downside+64.2%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($2.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$86.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-26.02% Return on Assets-24.94% Debt Debt-to-Equity RatioN/A Current Ratio18.08 Quick Ratio18.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.22 per share Price / Book6.44Miscellaneous Outstanding Shares48,160,000Free Float33,187,000Market Cap$2.55 billion OptionableOptionable Beta0.10 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:MBX) was last updated on 10/27/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
